Cellular and molecular outcomes of glutamine supplementation in the brain of succinic semialdehyde dehydrogenase‐deficient mice

• Published in: JIMD reports Vol. 56; no. 1; pp. 58 - 69
• Main Authors: Brown, Madalyn N., Gibson, K. Michael, Schmidt, Michelle A., Walters, Dana C., Arning, Erland, Bottiglieri, Teodoro, Roullet, Jean‐Baptiste
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.11.2020; Wiley
• Subjects: Antibodies; astrocyte; Dehydrogenases; Diet; dietary supplementation; GABA; Gene expression; Genotype & phenotype; GHB; glutamine; Homeostasis; Kinases; knockout mice; Laboratories; Metabolism; Metabolites; Microscopy; Proteins; Research Report; Research Reports; Software; Variance analysis; United States > US; California; GHB; GABA; knockout mice; glutamine; astrocyte; dietary supplementation
• ISSN: 2192-8312; 2192-8304; 2192-8312
• DOI: 10.1002/jmd2.12151

Succinic semialdehyde dehydrogenase deficiency (SSADHD) manifests with low levels of glutamine in the brain, suggesting that central glutamine deficiency contributes to pathogenesis. Recently, we attempted to rescue the disease phenotype of aldh5a1−/− mice, a murine model of SSADHD with dietary glutamine supplementation. No clinical rescue and no central glutamine improvement were observed. Here, we report the results of follow‐up studies of the cellular and molecular basis of the resistance of the brain to glutamine supplementation. We first determined if the expression of genes involved in glutamine metabolism was impacted by glutamine feeding. We then searched for changes of brain histology in response to glutamine supplementation, with a focus on astrocytes, known regulators of glutamine synthesis in the brain. Glutamine supplementation significantly modified the expression of glutaminase (gls) (0.6‐fold down), glutamine synthetase (glul) (1.5‐fold up), and glutamine transporters (solute carrier family 7, member 5 [slc7a5], 2.5‐fold up; slc38a2, 0.6‐fold down). The number of GLUL‐labeled cells was greater in the glutamine‐supplemented group than in controls (P < .05). Reactive astrogliosis, a hallmark of brain inflammation in SSADHD, was confirmed. We observed a 2‐fold stronger astrocyte staining in mutants than in wild‐type controls (optical density/cell were 1.8 ± 0.08 in aldh5a1−/− and 0.99 ± 0.06 in aldh5a1+/+; P < .0001), and a 3‐fold higher expression of gfap and vimentin. However, glutamine supplementation did not improve the histological and molecular signature of astrogliosis. Thus, glutamine supplementation impacts genes implicated in central glutamine homeostasis without improving reactive astrogliosis. The mechanisms underlying glutamine deficiency and its contribution to SSADHD pathogenesis remain unknown and should be the focus of future investigations.